By Cecilia Butini


Sanofi SA said Wednesday that it has entered into an agreement with BioNTech SE to support the manufacture and supply of the coronavirus vaccine that it is co-developing with Pfizer Inc.

The French pharmaceutical major said it will provide BioNTech with access to its production infrastructure to supply more than 125 million vaccine doses to the European Union. Initial supplies will come from Sanofi's sites in Frankfurt from the summer 2021, it said.

Sanofi added that it is continuing the development of two vaccine candidates against Covid-19, saying that in February 2021 it plans to initiate a new Phase 2 study of the recombinant protein-based vaccine that it is developing with GlaxoSmithKline PLC. The company is also developing a messenger-RNA vaccine in partnership with Translate Bio Inc., it said.


Write to Cecilia Butini at


(END) Dow Jones Newswires

January 27, 2021 02:03 ET (07:03 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.